Cellular B-2 Microglobulin Expression as a Prognostic Indicator in Renal Cell Carcinoma

Authors

  • I. Levin Department of Urology, Institute of Pathology, Unit of Epidemiology, and Unit of Immunology and Microbiology, The Soroka Medical Center and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel; The Department of Oncology, Beilinson Medical Center, Petah Tikva and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
  • O. Kuperman Department of Urology, Institute of Pathology, Unit of Epidemiology, and Unit of Immunology and Microbiology, The Soroka Medical Center and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel; The Department of Oncology, Beilinson Medical Center, Petah Tikva and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
  • J. Goldstein Department of Urology, Institute of Pathology, Unit of Epidemiology, and Unit of Immunology and Microbiology, The Soroka Medical Center and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel; The Department of Oncology, Beilinson Medical Center, Petah Tikva and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
  • L. Neumann Department of Urology, Institute of Pathology, Unit of Epidemiology, and Unit of Immunology and Microbiology, The Soroka Medical Center and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel; The Department of Oncology, Beilinson Medical Center, Petah Tikva and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
  • S. Segal Department of Urology, Institute of Pathology, Unit of Epidemiology, and Unit of Immunology and Microbiology, The Soroka Medical Center and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel; The Department of Oncology, Beilinson Medical Center, Petah Tikva and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
  • J. Kaneti Department of Urology, Institute of Pathology, Unit of Epidemiology, and Unit of Immunology and Microbiology, The Soroka Medical Center and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel; The Department of Oncology, Beilinson Medical Center, Petah Tikva and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
  • L. Lismer Department of Urology, Institute of Pathology, Unit of Epidemiology, and Unit of Immunology and Microbiology, The Soroka Medical Center and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel; The Department of Oncology, Beilinson Medical Center, Petah Tikva and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
  • A. Machpud Department of Urology, Institute of Pathology, Unit of Epidemiology, and Unit of Immunology and Microbiology, The Soroka Medical Center and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel; The Department of Oncology, Beilinson Medical Center, Petah Tikva and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
  • B. Klein Department of Urology, Institute of Pathology, Unit of Epidemiology, and Unit of Immunology and Microbiology, The Soroka Medical Center and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel; The Department of Oncology, Beilinson Medical Center, Petah Tikva and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

DOI:

https://doi.org/10.3109/02841869109088247

Keywords:

Renal cell carcinoma, B-2 microglobulin, survival

Abstract

The expression of B-2 microglobulin (B-2M) on tumor cells and their normal cell counterparts in 39 patients with renal cell carcinoma was studied and correlated to tumor stage and survival. The median survival time of patients with localized disease (stage I) whose tumors expressed B-2M was 10.2 years while the median survival time for patients whose tumors did not express B-2M was only 3.6 years (p < 0.001). For patients with more advanced disease (stages II, 111, IV) whose tumors expressed B-2M, median survival time was 3.6 years compared to 2.0 years in patients whose tumors did not express B-2M, a non-significant difference. It is suggested that the tumor cell membrane expression of B-2M may serve as an indicator of good prognosis in early renal cell carcinoma.

Downloads

Download data is not yet available.

Downloads

Published

1991-01-01

How to Cite

Levin, I., Kuperman, O., Goldstein, J., Neumann, L., Segal, S., Kaneti, J., … Klein, B. (1991). Cellular B-2 Microglobulin Expression as a Prognostic Indicator in Renal Cell Carcinoma. Acta Oncologica, 30(8), 941–945. https://doi.org/10.3109/02841869109088247

Issue

Vol. 30 No. 8 (1991): Acta Oncologica

Section

Articles